Explore all subjects

The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

All GLG News Analyses Filed Under: Endocrinology

Analyses are solely the work of the authors and have not been edited or endorsed by GLG.
Analysis of: Frost & Sullivan Acknowledges MannKind’s Path-breaking Solution to Treat Diabetes | /www.frost.com/prod/servlet/press-release.pag?docid=93822443
Inhaled insulin should be prescribed to the truly needle phobic, of which there are few and far between.      
Analysis of: Lilly Introduces World's First Digital Insulin Pen With Memory | www.medicalnewstoday.com
The Lilly Pen is high on technology, low on what patients need.
March 19, 2007
Mind/Body Connection
Analysis of: Together Diabetes And Depression Increase Risk To Heart Patients | www.medicalnewstoday.com
The mind cannot only heal, it can cause infirmity. Heal the mind, the body will follow.
John Spurlock, MD, Medical Director
John Spurlock, MD, Medical Director
Continence Management Institute of the LeHigh Valley
Analysis of: Together Diabetes And Depression Increase Risk To Heart Patients | www.medicalnewstoday.com
1. Diabetes and depression increases risk of heart disease2. This study will lead to greater prescribing of anti depression medication to diabetics.3. Depressed diabetics may lack motivation to control diabetes
Analysis of: Savient Announces Completion of Patient Enrollment in Phase 3 Trials of Puricase(R) for Treatment-Failure Gout | investor.savient.com
If all goes well, this will be second line therapy for chronic gout.
March 12, 2007
Is newer better?
Analysis of: Savient Announces Completion of Patient Enrollment in Phase 3 Trials of Puricase(R) for Treatment-Failure Gout | investor.savient.com
A newer agent is being introduced for patients with hyperuricemia and gout, but where does this medication fit into the treatment paradigm?Will this medication be used more in the rheumatologic arena or will primary care doctors be facile with this new option?
Charles Glueck, MD, Medical Research Director of Cholesterol Center
Charles Glueck, MD, Medical Research Director of Cholesterol Center
Jewish Hospital
Analysis of: CETP INHIBITORS: A PROBABLE CLASS ACTION EFFECT TO BE PROATHEROGENIC | mediaroom.pfizer.com
By reducing fractional catabolic rate and by producing a large, cholesterol rich HDL molecule which could not easily be cleared by hepatic HDL receptors, our research group in Cincinnati thought from the beginning that the CETP inhibitors AS A CLASS would fail, and might even be proatherogenic. Regrettably,...
March 6, 2007
Boon for IDDM
Analysis of: Lilly Introduces World's First Digital Insulin Pen With Memory | www.medicalnewstoday.com
This new device will allow patients and their physicians the ability to track and modify S.Q. insulin to allow for better understanding of how much insulin to use and so achieve better diabetes control.
Analysis of: Lilly Introduces World's First Digital Insulin Pen With Memory | www.medicalnewstoday.com
Lilly and Novo were tied for the best rapid-acting insulin products, Humalog and Novolog, respectively.  Now, Lilly has pulled way ahead with the new Memoir Pen.
Analysis of: Diabetes Risk Factors Develop Earlier In Women Than Men | www.medicalnewstoday.com
Any new screening strategy needs to keep the financial impact in mind. Also, with any screening test, we need to know if earlier detection will significantly change outcomes.
Previous Page : 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 Next301 to 310 of 375
Subscribe to Updates

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines

Become a GLG Client to speak with any expert

GLG's 850+ Clients Include:

Fortune 500®  companies
40 of the leading 50  global mutual funds
15 of the leading 20  global banks
8 of the leading 10  global private equity firms
5 of the top 10  AmLaw firms

Request more information







*Inquiries subject to client acceptance process


Analytics


Generated at 2009-01-08T19:00:17.880